Market closedNon-fractional

G1 Therapeutics/GTHX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About G1 Therapeutics

G1 Therapeutics Inc is a commercial-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat the types of cancer, such as cell lung cancer and breast cancer, and designs them to combine and enhance the anti-tumor activity of current therapies. Its product COSELA indicates to help protect bone marrow from the damage of chemotherapy.

Ticker

GTHX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Research Triangle Park, United States

Employees

100

G1 Therapeutics Metrics

BasicAdvanced
$131M
Market cap
-
P/E ratio
-$0.59
EPS
1.71
Beta
-
Dividend rate
$131M
1.71
2.94
2.357
148.322
169.757
-2.56%
-10.81%
-84.13%
1.549
4.75
4.75
-7.16
46.55%
-78.42%
12.20%
-37.70%

What the Analysts think about G1 Therapeutics

Analyst Ratings

Majority rating from 6 analysts.
Buy

G1 Therapeutics Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-70.83% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$14M
-2.70%
Net income
-$10M
-5.56%
Profit margin
-70.83%
-2.93%

G1 Therapeutics Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 2.72%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.14
-$0.35
-$0.21
-$0.20
-
Expected
-$0.22
-$0.33
-$0.28
-$0.21
-$0.17
Surprise
-164.00%
6.38%
-23.69%
-2.72%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for G1 Therapeutics stock?

G1 Therapeutics (GTHX) has a market cap of $131M as of July 06, 2024.

What is the P/E ratio for G1 Therapeutics stock?

The price to earnings (P/E) ratio for G1 Therapeutics (GTHX) stock is 0 as of July 06, 2024.

Does G1 Therapeutics stock pay dividends?

No, G1 Therapeutics (GTHX) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next G1 Therapeutics dividend payment date?

G1 Therapeutics (GTHX) stock does not pay dividends to its shareholders.

What is the beta indicator for G1 Therapeutics?

G1 Therapeutics (GTHX) has a beta rating of 1.71. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell G1 Therapeutics stock

Buy or sell G1 Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing